Effectiveness and safety of drugs in individuals of different skin colors and ethnic groups with genetic polymorphism in the cytochrome P-450 enzymatic system: a systematic review
DOI:
https://doi.org/10.33448/rsd-v11i11.33628Keywords:
Pharmacogenomic Study; Pharmacokinetics; Ethnic Health; Precision Medicine; Evidence-based medicine.Abstract
The objective was to review, among individuals of different skin colors and ethnic groups, how the effectiveness and safety of drugs could be influenced by pharmacokinetics variations resulting from genetic polymorphisms in the cytochrome P-450 enzyme system (CYP-450). This is a systematic review study, with a descriptive and observational approach. The systematic review protocol was registered on the international platform Prospective Register of Systematic Reviews under the identification number 25581111. Data collection was performed on Medical Literature Analysis and Retrieval System Online (MedLine) through PubMed, Latin American Literature, and the Caribbean Health Sciences (LILACS), as well as the Scientific Electronic Library Online (SciELO). Six CY450 genetic polymorphisms that may affect pharmacodynamic and pharmacokinetics parameters of therapy in drug users of different ethnic and skin color was identified and described to drugs as Olanzapine, Efavirenz, and Irinotecan. However, the results found did not demonstrate the existence of clinically significant differences when evaluating the aspects of safety and effectiveness of the drugs, despite the identification of polymorphisms in the CYP450 enzyme system that influenced these parameters. The findings point to the identification of individual genotypes, without ethnic or skin color cut, to provide a better application of precision medicine, thus helping to make therapeutic decisions in clinical practice in the light Evidence-Based medicine.
References
Amstutz, U. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing. Clinical Pharmacology & Therapeutics. 2017 Update. 10.1002/cpt.911
Bandeira, C. M.; et al (2014) polymorphisms in the Cytochrome P450 family and squamous cell carcinoma of the oral cavity, pharynx and larynx. Rev. Col. Bras. Cir., 41(5), 366-3722014.
Barata, R. B. Como e por que as desigualdades sociais fazem mal à saúde. Editora FIOCRUZ. 2009
Bigos et al. (2011) Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol. Psychiatry. 16(6), 620-625.
Brito, R. B. de. Farmacogenética em psiquiatria: influência dos polimorfismos CYP1A2*1F E CYP2C19*17 na refratariedade ao tratamento à clozapina e ao escitalopram. Tese (Doutorado em Ciências Biológicas), Universidade Federal de Goiás. Goiânia, 877.
Carrera, J. de S. (2015) Polimorfismo do gene UGT1A1 associado à toxicidade em pacientes oncológicos tratados com irinotecano em Belém/Pará. Dissertação (Oncologia e Ciências Médicas), Universidade Federal do Pará. Belém, p.63. 2015.
Carvalho, L. B. L. (2018) Polimorfismos em genes envolvidos nas vias de absorção, distribuição, metabolização e excreção, (ADME) de fármacos e sua relação com a falha virológica da terapia anti-HIV. Dissertação (Programa de Pós Graduação em Genética), Universidade Federal de Pernambuco. Pernambuco, p.81.
Costa, P. do S. S. (2018) Estudo farmacogenético da resposta ao tratamento do eritema nodoso hansênico. Tese (Genética e Biologia Molecular), Universidade Federal do Rio Grande do Sul. Porto Alegre, p.78.
Cummins, N. W. et al. (2015) Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. E. Bio. Medicine. 2(7), 706-712.
Desta, Z. et al. (2019) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clinical Pharmacology & Therapeutics. 106(4). 8, 10.1002/cpt.1477
Dúran, M. Á. C. Avaliação de polimorfismos dos genes timidilato sintase, metileno-tetrahidrofolato redutase e metionina sintase em tumores da mama. Dissertação (Mestrado em Neurociências e Biologia Celular), Universidade Federal do Pará. Belém, 2019.
Ferreira, A. de J. & Ferreira, S. A. (2011) Raça/etnia, gênero e suas implicações na construção das identidades sociais em sala de aula de línguas. Revista Virtual de Letras, 3(2).
Gong, M. et al. (2012) Genetic polymorphisms of GSTM1, GSTT1, and GSTP1 with prostate cancer risk: a meta-analysis of 57 studies. PLoS One. San Francisco, (7)
He, Y-F. et al (2008) Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J. Clin. Pharm. Ther. 33(3), 307-317.
Kap, J. E. et al. (2014) Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Pharmacogenet. Genomics. 24(7), 340-347.
Klomp, S. D. et al. (2020) Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of Clinical Medicine. 9(9).
Lamba, V. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol Exp Ther. 307(3), 902-922.
Leitão, L. P. C. (2018) Variabilidade do gene CYP2D6 em populações ameríndias. Dissertação (Mestrado em Oncologia e Ciências Médicas), Universidade Federal do Pará. Belém, 89.
Martins, C. G., Wagner, S. C.; & Linden, R. (2013) Individualização Farmacocinética das Doses de 5-Fluoruracil no Câncer Colorretal. Rev. Bras. Cancerol. 59(2), 271-280.
Mcgraw, J. & Waller, D. (2012) Cytochrome P450 variations in different ethnic populations. Drug Metab. Toxicol. 8, 371–382.
Meyer, U., A. (2004) Pharmacogenetics — five decades of therapeutic lessons from genetic diversity. Nature Rev. Gen. 5(9), 669-676.
Mhandire, D. et al. (2015) Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. A Journal of Integrative Biology. 19: 553-562.
Mollan et al. (2017) Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. J. Infec. Dis. 1(216), 564.
Mora et al. (2015) CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs. Clin. Exp. Pharmacol. 5(3).
Neto, O. J. V. (2018) Avaliação de estratégias de fenotipagem da enzima diidropirimidina desidrogenase na predição da exposição ao 5-fluorouracil e a ocorrência de toxicidade grave à quimioterapia em pacientes com neoplasia gastrointestinal. Dissertação (Mestrado em Toxicologia e Análises Toxicológicas), Universidade Feevale. Novo Hamburgo, Rio Grande do Sul, p.70.
Ngaimisi, E., et al. (2013) Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. Plos One.
Nguyen, H. H. et al. (2019) Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population. Medicine. Baltimore, 9(22), 1-9.
Nicola, B. V. de. (2019) Farmacogenética do lítio: marcadores de refratariedade em pacientes com transtorno bipolar. Dissertação (Programa de Psiquiatria), Universidade de São Paulo. p.95.
Offer, S. M. et al. (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 73(6), 2545-2554.
Offer, S. M. et al. (2013) Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73(6), 1958-1968.
República dos Estados Unidos da América (EUA). Clinical Pharmacogenetics Implementation Consortium (CPIC), 2020a.
República dos Estados Unidos da América (EUA). Food and Drug Administration. Table Pharmacogenetic Associations, 2021.
República dos Estados Unidos da América (EUA). Pharmacogene Variation Consortium (PharmVar), 2020b.
Sanoff et al. (2009) Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J. Clin. Oncol. Sep 1(27). 4109-4115.
Santos, D. J. da S. et al. (2010) Raça versus etnia: diferenciar para melhor aplicar. Dental Press J. Orthod., 15(3), 121-124.
Santos, J. da R. dos. (2015) Avaliação farmacogenética em pacientes tratados com fármacos antitabagismo. Dissertação (Mestrado em Ciências Médicas) – Universidade de São Paulo. p.79
Shrestha, S. et al. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin. Pharmacol. Ther. 104(4), 709-718.
Silva, C. N. da et al. (2015) Polimorfismo nulo dos genes GSTM1 e GSTT1 na suscetibilidade do câncer renal: evidências baseadas em meta-análise. Jornal Brasileiro de Nefrologia 37(2), 248-254.
Soriano, A. et al. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol. 25(5), 627-632, 2011.
Valeriano, J. J. de L. S. (2016) Polimorfismos genéticos associados a efeitos adversos neuropsiquiátricos em pacientes HIV positivos submetidos à terapia com Efavirenz. Dissertação (Mestrado em Genética), Universidade Federal de Pernambuco. Recife, p.129.
Wei X-X. et al. (2019) Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics. 20(4), 241-249.
Zanger, U. M. & Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141.
Zhang, Y. et al. (2010) Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients. Journal of the International AIDS Society 13(183).
Zhou, Y., Ingelman-Sundberg & M.; Lauschke, V. M. (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clinical Pharmacology & Therapeutis Journal. 102(4), 688-700.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Luiz Eduardo Oliveira Matos; Rafael Ciro Marques Cavalcante; Gisele de Carvalho Brito; Keila Eduarda Pereira dos Santos; Ivana Beatrice Mânica da Cruz; Giancarllo Danezi Felin; Giulliano Danezi Felin; Tais Cristina Unfer
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
